Published in Gut on July 01, 1999
Helicobacter pylori eradication versus prokinetics in the treatment of functional dyspepsia: a randomized, double-blind study. J Gastroenterol (2006) 1.62
Helicobacter pylori in colorectal neoplasms: is there an aetiological relationship? World J Surg Oncol (2007) 0.98
A comparison of the clinical, demographic and psychiatric profiles among patients with erosive and non-erosive reflux disease in a multi-ethnic Asian country. World J Gastroenterol (2005) 0.88
The relationship between helicobacter pylori infection and gastro-esophageal reflux disease. N Am J Med Sci (2011) 0.77
Campylobacter pylori and duodenal ulcers: the gastrin link. Lancet (1989) 9.76
Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology (1997) 8.51
Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration, and gastric pathology. Lancet (1991) 6.73
Helicobacter pylori and atrophic gastritis: importance of the cagA status. J Natl Cancer Inst (1995) 6.07
Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. N Engl J Med (1982) 5.07
Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med (1996) 4.11
Symptoms in gastro-oesophageal reflux disease. Lancet (1990) 4.10
Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology (1993) 3.98
Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis (1976) 3.71
Mechanisms of lower oesophageal sphincter incompetence in patients with symptomatic gastrooesophageal reflux. Gut (1988) 3.45
Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology (1995) 3.28
Serologic detection of infection with cagA+ Helicobacter pylori strains. J Clin Microbiol (1995) 3.23
An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res (1998) 3.22
Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology (1997) 3.16
Esophageal peristaltic dysfunction in peptic esophagitis. Gastroenterology (1986) 3.16
Transient lower esophageal sphincter relaxation. Gastroenterology (1995) 2.91
Inflammation and intestinal metaplasia of the gastric cardia: the role of gastroesophageal reflux and H. pylori infection. Gastroenterology (1998) 2.74
Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion (1992) 2.40
Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. Gastroenterology (1995) 2.23
The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology (1998) 2.14
Inappropriate hypergastrinaemia in asymptomatic healthy subjects infected with Helicobacter pylori. Gut (1990) 2.13
Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol (1995) 2.12
Gastric emptying in patients with gastroesophageal reflux. Gastroenterology (1981) 2.02
One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group. Gut (1997) 2.00
Prevalence of symptoms suggestive of gastro-oesophageal reflux disease in an adult population. Ann Med (1995) 1.97
Treatment of ulcerative reflux oesophagitis with colloidal bismuth subcitrate in combination with cimetidine. Gut (1988) 1.91
Intestinal metaplasia at the squamocolumnar junction in patients attending for diagnostic gastroscopy. Gut (1997) 1.88
Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet (1992) 1.88
Gastric acid hypersecretion in refractory gastroesophageal reflux disease. Gastroenterology (1990) 1.77
Prevalence of Campylobacter pylori in esophagitis, gastritis, and duodenal disease. Arch Intern Med (1989) 1.77
Are clinical patterns of dyspepsia a valid guideline for appropriate use of endoscopy? A report on 2253 dyspeptic patients. Am J Gastroenterol (1993) 1.74
Plasma gastrin, daytime intragastric pH, and nocturnal acid output before and at 1 and 7 months after eradication of Helicobacter pylori in duodenal ulcer subjects. Scand J Gastroenterol (1991) 1.72
Is Barrett's metaplasia the source of adenocarcinomas of the cardia? Arch Surg (1994) 1.68
Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology (1996) 1.67
Alterations in upper gastrointestinal motility in Helicobacter pylori-positive nonulcer dyspepsia. Am J Gastroenterol (1994) 1.59
Inflammation and specialized intestinal metaplasia of cardiac mucosa is a manifestation of gastroesophageal reflux disease. Ann Surg (1997) 1.58
Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis. Dig Dis Sci (1997) 1.46
Intestinal metaplasia of the gastric cardia. Am J Gastroenterol (1997) 1.45
The incidence of reflux esophagitis among the Chinese. Am J Gastroenterol (1997) 1.43
Helicobacter pylori infection and gastric function in patients with chronic idiopathic dyspepsia. Gastroenterology (1992) 1.40
Relations among autonomic nerve dysfunction, oesophageal motility, and gastric emptying in gastro-oesophageal reflux disease. Gut (1991) 1.37
The gastric cardia in Helicobacter pylori infection. Hum Pathol (1994) 1.35
Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut (1995) 1.30
Evaluation of Helicobacter pylori in reflux oesophagitis and Barrett's oesophagus. Gut (1997) 1.22
Intragastric distribution and gastric emptying of solids and liquids in functional dyspepsia. Lack of influence of symptom subgroups and H. pylori-associated gastritis. Dig Dis Sci (1993) 1.20
Canadian Helicobacter pylori consensus conference. Canadian Association of Gastroenterology. Can J Gastroenterol (1998) 1.19
Helicobacter pylori and gastro-oesophageal reflux disease--a prospective study. Ir J Med Sci (1994) 1.16
Epidermal growth factor receptors in the oesophagus. Gut (1992) 1.15
Relation between gastric cancer and previous peptic ulcer disease. Gut (1997) 1.14
Clinical and manometric findings in benign peptic strictures of the esophagus. Dig Dis Sci (1979) 1.11
Helicobacter pylori in 205 consecutive endoscopy patients. Scand J Infect Dis (1993) 1.09
Multivariate analysis of pathophysiological factors in reflux oesophagitis. Gut (1997) 1.08
Patterns of colonisation of Campylobacter pylori in the oesophagus, stomach and duodenum. Gut (1989) 1.06
Endoscopic findings and diagnoses in unselected dyspeptic patients at a primary health care center. Scand J Gastroenterol (1989) 1.03
Effect of bile salts on the ionic permeability of the esophageal mucosa and their role in the production of esophagitis. Gastroenterology (1975) 1.01
The prevalence of esophagitis in patients with duodenal ulcer or ulcer-like dyspepsia. Am J Gastroenterol (1996) 0.98
Reflux oesophagitis and Helicobacter pylori infection in elderly patients. Postgrad Med J (1996) 0.96
The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther (1995) 0.96
Mechanisms of H+ injury in rabbit esophageal epithelium. Am J Physiol (1984) 0.94
The association of histologic gastritis with gastroesophageal reflux and delayed gastric emptying. J Clin Gastroenterol (1984) 0.90
Campylobacter pylori is not associated with gastroparesis. Dig Dis Sci (1989) 0.90
Barrett's oesophagus and Helicobacter pylori. J Gastroenterol Hepatol (1995) 0.88
Symptoms and disease severity in gastro-oesophageal reflux disease. Scand J Gastroenterol Suppl (1994) 0.85
Different management for Helicobacter pylori positive and negative patients with gastro-oesophageal reflux disease? Gut (1998) 0.83
Helicobacter pylori and acid peptic disorders of the esophagus: is it conceivable? Am J Gastroenterol (1997) 0.82
Different interdigestive antroduodenal motility patterns in chronic antral gastritis with and without Helicobacter pylori infection. Dig Dis Sci (1993) 0.78
Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut (2006) 9.03
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis (2010) 6.75
Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther (2002) 6.17
Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European study group. Lancet (1999) 5.27
Campylobacter pylori and recurrence of duodenal ulcers--a 12-month follow-up study. Lancet (1987) 4.32
Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter (1996) 3.13
Long-term prospective study of Helicobacter pylori in nonulcer dyspepsia. Dig Dis Sci (1995) 2.75
Absorption of 51chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease. Gastroenterology (1983) 2.23
Helicobacter pylori: the cancer link. J R Soc Med (1996) 2.15
Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother (1999) 2.07
Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther (2015) 2.00
One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group. Gut (1997) 2.00
Elemental diets in treatment of acute Crohn's disease. Br Med J (1980) 1.92
European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut (2006) 1.87
Nature meets nurture: molecular genetics of gastric cancer. Hum Genet (2009) 1.87
Current European concepts in the management of Helicobacter pylori infection--the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol (1997) 1.81
Duodeno-jejunal adenocarcinoma as a first presentation of coeliac disease. J Clin Pathol (1996) 1.70
The effect of bile acids on the growth and adherence of Helicobacter pylori. Aliment Pharmacol Ther (1991) 1.56
Gallstone clearance: a randomized study of extracorporeal shock wave lithotripsy and chemical dissolution. Br J Surg (1990) 1.54
Comparison of tests for assessment of Helicobacter pylori eradication: results of a multi-centre study using centralized facility testing. Eur J Gastroenterol Hepatol (2000) 1.41
Colorectal adenoma characteristics as predictors of recurrence. Dis Colon Rectum (2004) 1.38
Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther (2005) 1.34
Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut (2005) 1.26
Noninvasive antigen-based assay for assessing Helicobacter pylori eradication: a European multicenter study. The European Helicobacter pylori HpSA Study Group. Am J Gastroenterol (2000) 1.26
Public awareness of risk factors and screening for colorectal cancer in Europe. Eur J Cancer Prev (2004) 1.25
Helicobacter pylori and duodenal ulcer recurrence. Am J Gastroenterol (1992) 1.24
Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther (2011) 1.22
Gastric epithelial cell kinetics in the progression from normal mucosa to gastric carcinoma. Gut (1996) 1.19
Vasoactive intestinal peptide concentrations and immunocytochemical studies in rectal biopsies from patients with inflammatory bowel disease. Gut (1984) 1.17
Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate. Gut (1990) 1.15
Effect of eradication of Helicobacter pylori infection on gastric epithelial cell proliferation. Dig Dis Sci (1995) 1.14
The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther (1999) 1.13
Extension of selection criteria for extracorporeal shock wave lithotripsy for gall stones. BMJ (1989) 1.09
The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther (1999) 1.08
Percutaneous endoscopic gastrostomy--its application in patients with neurological disease. Ir J Med Sci (1993) 1.07
Eradicating Helicobacter pylori and symptoms of non-ulcer dyspepsia. BMJ (1991) 1.06
Workgroup II: the screening process. UICC International Workshop on Facilitating Screening for Colorectal Cancer, Oslo, Norway (29 and 30 June 2002). Ann Oncol (2005) 1.03
Validation of the Capsule Endoscopy Crohn's Disease Activity Index (CECDAI or Niv score): a multicenter prospective study. Endoscopy (2011) 1.02
Atraumatic non-distorting pyloric sphincter pressure studies. Gut (1980) 0.98
Analysis of drug resistance and virulence-factor genotype of Irish Helicobacter pylori strains: is there any relationship between resistance to metronidazole and cagA status? Aliment Pharmacol Ther (2009) 0.97
Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis. Aliment Pharmacol Ther (2004) 0.96
Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations. Gut (1990) 0.96
Helicobacter pylori eradication--a surrogate marker for duodenal ulcer healing. Eur J Gastroenterol Hepatol (1996) 0.95
Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study Group. Aliment Pharmacol Ther (1998) 0.95
CARD4/NOD1 is not involved in inflammatory bowel disease. Gut (2003) 0.94
Review article: Reproduction in the patient with inflammatory bowel disease. Aliment Pharmacol Ther (2007) 0.92
Proposal for use of a standard side effect scoring system in studies exploring Helicobacter pylori treatment regimens. Eur J Gastroenterol Hepatol (1996) 0.92
Biochemical analysis of enzymic markers of inflammation in rectal biopsies from patients with ulcerative colitis and Crohn's disease. J Clin Pathol (1983) 0.90
Effects of vitamin antioxidant supplementation on cell kinetics of patients with adenomatous polyps. Gut (1993) 0.90
Histological gastritis in duodenal ulcer: relationship to Campylobacter pylori and effect of ulcer therapy. Am J Gastroenterol (1988) 0.89
Epithelial patchy necrosis in Crohn's disease. Hum Pathol (1983) 0.89
Evaluation of different solid media used for cultivation of Helicobacter (Campylobacter) pylori. Indian J Med Res (1992) 0.88
Review article: use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception. Aliment Pharmacol Ther (2008) 0.88
Piezoelectric lithotripsy for gallstones: analysis of results in patients with extended selection. Br J Surg (1991) 0.88
High prevalence of vitamin D insufficiency in healthy Irish adults. Ir J Med Sci (2008) 0.88
Subcellular fractionation of rectal biopsy homogenates from patients with inflammatory bowel disease. Scand J Gastroenterol (1985) 0.86
Prevalence of Helicobacter pylori in non-ulcer dyspepsia. Aliment Pharmacol Ther (1995) 0.86
Short report: high-dose omeprazole and amoxycillin in the treatment of Helicobacter pylori-associated duodenal ulcer. Aliment Pharmacol Ther (1993) 0.86
Who should be treated for Helicobacter pylori infection? A review of consensus conferences and guidelines. Gastroenterology (1997) 0.85
Does Helicobacter pylori eradication affect symptoms in nonulcer dyspepsia: a 5-year follow-up study. Helicobacter (2002) 0.85
Assessment of the clinical significance of intestinal spirochaetosis. J Clin Pathol (2008) 0.85
Coeliac disease in Europe. Aliment Pharmacol Ther (2003) 0.84
Review article: non-steroidal anti-inflammatory drugs and Helicobacter pylori. Aliment Pharmacol Ther (2000) 0.84
Short report: treatment of Helicobacter pylori-associated duodenal ulcer with omeprazole plus antibiotics. Aliment Pharmacol Ther (1993) 0.84
Consensus guidelines: agreement and debate surrounding the optimal management of Helicobacter pylori infection. Can J Gastroenterol (2000) 0.83
Helicobacter pylori resistance rates for levofloxacin, tetracycline and rifabutin among Irish isolates at a reference centre. Ir J Med Sci (2013) 0.83
Helicobacter pylori and gastric cancer. Ital J Gastroenterol Hepatol (1998) 0.83
Tonsillectomy and inflammatory bowel disease location. Eur J Gastroenterol Hepatol (1997) 0.83
Carditis: all Helicobacter pylori or is there a role for gastro-oesophageal reflux? Scand J Gastroenterol (2002) 0.82
The safety and efficacy of tripotassium dicitrato bismuthate (De-Nol) maintenance therapy in patients with duodenal ulceration. Aliment Pharmacol Ther (1990) 0.82
HpSA: assessment of a new non-invasive diagnostic assay for Helicobacter pylori infection in an Irish population. Ir J Med Sci (1999) 0.82
New concepts concerning management of Helicobacter pylori infection: 2 years after the Maastricht Consensus Report. Ital J Gastroenterol Hepatol (1998) 0.82
Chemical gastritis induced by naproxen in the absence of Helicobacter pylori infection. J Clin Pathol (1995) 0.81
Impaired gut barrier function in malnourished patients. Br J Surg (1996) 0.81
Genetic Mechanisms and Aberrant Gene Expression during the Development of Gastric Intestinal Metaplasia and Adenocarcinoma. Curr Genomics (2007) 0.80
Ornithine decarboxylase G316A genotype and colorectal cancer risk. Colorectal Dis (2010) 0.80
Round one of the Adelaide and Meath Hospital/Trinity College Colorectal Cancer Screening Programme: programme report and analysis based on established international key performance indices. Ir J Med Sci (2011) 0.80
Diet and Crohn's disease. Mol Aspects Med (1987) 0.79
The effect of colonic site of biopsy on cell proliferation profiles using BRDU incorporation as a measure of cell proliferation. Eur J Cancer Prev (1992) 0.79
Culture of the organisms and histochemical identification. Scand J Gastroenterol Suppl (1988) 0.79
Elemental diets in the treatment of Crohn's disease. Proc Nutr Soc (1979) 0.79
Endoscopic surveillance of premalignant gastric lesions. Gut (2003) 0.78
The ECP calcium fibre polyp prevention study preliminary report. ECP Colon Group. Eur J Cancer Prev (1993) 0.78
Dosage of colloidal bismuth subcitrate in duodenal ulcer healing and clearance of Campylobacter pylori. Aliment Pharmacol Ther (1990) 0.78
Guidelines for the management of Helicobacter pylori-related upper gastrointestinal diseases. Irish Helicobacter Pylori Study Group. Ir J Med Sci (1997) 0.78
Chromosome 5q candidate genes in coeliac disease: genetic variation at IL4, IL5, IL9, IL13, IL17B and NR3C1. Tissue Antigens (2005) 0.78
Consensus or confusion: a review of existing national guidelines on Helicobacter pylori-related disease. Eur J Gastroenterol Hepatol (1997) 0.78
Monozygotic twins with Crohn's disease and ulcerative colitis: a unique case report. Gut (1997) 0.78
Organelle pathology in ulcerative and Crohn's colitis with special reference to the lysosomal alterations. Gut (1984) 0.78
Communication of information to patients with inflammatory bowel disease: A European Collaborative Study in a multinational prospective inception cohort. J Crohns Colitis (2008) 0.78
"Best practice' for Helicobacter pylori eradication in the primary care setting. Ir Med J (2006) 0.78
Omeprazole, amoxycillin and metronidazole for the cure of Helicobacter pylori infection. Eur J Gastroenterol Hepatol (1999) 0.77
Population differences in intestinal permeability to chromium EDTA. Ir J Med Sci (1988) 0.77
Helicobacter pylori infection and gastric cancer: usefulness of screening high risk groups. Acta Gastroenterol Belg (1996) 0.76
RIP2 polymorphisms in inflammatory bowel diseases. Inflamm Bowel Dis (2011) 0.76
Short report: short-term triple therapy for H. pylori-associated duodenal ulcer disease. Aliment Pharmacol Ther (1992) 0.76